First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia


Study Number
84119
Phase
I
Age Group
Adult
Purpose

This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess ziftomenib (KO-539), a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML).

Full Title

A Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor
KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

ClinicalTrials.Gov ID
NCT04067336

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.